Fulgent Genetics Inc. (FLGT)
| Bid | 16.69 |
| Market Cap | 522.71M |
| Revenue (ttm) | 285.11M |
| Net Income (ttm) | -42.96M |
| EPS (ttm) | -1.41 |
| PE Ratio (ttm) | -12.02 |
| Forward PE | -37.03 |
| Analyst | Hold |
| Ask | 17.11 |
| Volume | 453,815 |
| Avg. Volume (20D) | 441,900.9 |
| Open | 17.21 |
| Previous Close | 17.09 |
| Day's Range | 16.85 - 17.36 |
| 52-Week Range | 14.57 - 25.11 |
| Beta | 1.54 |
About FLGT
Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions; solid tumor molecular profiling for somatic cancer testing; rapid whole genome testing for children i...
Analyst Forecast
According to 1 analyst ratings, the average rating for FLGT stock is "Hold." The 12-month stock price forecast is $16, which is a decrease of -5.63% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
3 weeks ago · seekingalpha.com
Fulgent Genetics, Inc. (FLGT) Q4 2024 Earnings Conference Call TranscriptFulgent Genetics, Inc. (NASDAQ:FLGT ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Melanie Solomon - IR Ming Hsieh - Chairman and CEO Brandon Perthuis - Chief Com...
3 weeks ago · businesswire.com
Fulgent Reports Fourth Quarter and Full Year 2024 Financial ResultsEL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeuti...
